-
1 Comment
Shanghai RAAS Blood Products Co., Ltd is currently in a long term downtrend where the price is trading 6.6% below its 200 day moving average.
From a valuation standpoint, the stock is 74.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16.8.
Shanghai RAAS Blood Products Co., Ltd's total revenue rose by 17.8% to $729M since the same quarter in the previous year.
Its net income has increased by 106.7% to $399M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.1% to $107M since the same quarter in the previous year.
Based on the above factors, Shanghai RAAS Blood Products Co., Ltd gets an overall score of 2/5.
| Industry | Biotechnology |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100000C31 |
| Sector | Healthcare |
| Exchange | SHE |
| Market Cap | 45B |
|---|---|
| PE Ratio | 20.36 |
| Target Price | 6.8 |
| Dividend Yield | 1.0% |
| Beta | 0.54 |
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002252.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
